BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6854135)

  • 41. Plasma concentrations of platelet factor 4 in acute myocardial infarction.
    Wadenvik H; Eriksson KA; Safai-Kutti S; Swedberg K; Kutti J
    Scand J Haematol; 1981 May; 26(5):359-63. PubMed ID: 7336149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exercise induces in vivo platelet activation in patients with coronary artery disease and in healthy individuals.
    Schernthaner G; Mühlhauser I; Böhm H; Seebacher C; Laimer H
    Haemostasis; 1983; 13(6):351-7. PubMed ID: 6230298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platelet consumption and plasma concentration of platelet factor 4 (PF-J).
    Gjesdal K; Abrahamsen AF
    Scand J Haematol; 1976 Jul; 17(1):5-9. PubMed ID: 959773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of two techniques for obtaining samples for coagulation studies: venipuncture and intraarterial line.
    Kaplow R
    Heart Lung; 1988 Nov; 17(6 Pt 1):651-3. PubMed ID: 3192410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An inverse relation between platelet factor 4 in the platelet and in the plasma.
    O'Brien JR; Etherington MD
    Thromb Haemost; 1976 Dec; 36(3):649-51. PubMed ID: 1037162
    [No Abstract]   [Full Text] [Related]  

  • 46. [Studies on the platelet factor 4. I. Relationship of Pf 4 to haemorrhage (author's transl)].
    Matsuoka M; Hoshiyama M; Shinada S; Sakuragawa N
    Rinsho Ketsueki; 1975 Oct; 16(10):936-45. PubMed ID: 1239528
    [No Abstract]   [Full Text] [Related]  

  • 47. Platelet factor 4 release during exercise in patients with coronary artery disease.
    Levine SP; Suarez AJ; Sorenson RR; Raymond NM; Knieriem LK
    Am J Hematol; 1984 Aug; 17(2):117-27. PubMed ID: 6147087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Observations on serum and red blood cell magnesium changes in treadmill exercise-induced cardiac ischemia.
    Chadda KD; Cohen J; Werner BM; Gorfien P
    J Am Coll Nutr; 1985; 4(2):157-63. PubMed ID: 4019938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The importance of blood collection methods for assessment of platelet activation.
    Levine SP; Suarez AJ; Sorenson RR; Knieriem LK; Raymond NM
    Thromb Res; 1981 Dec 1-15; 24(5-6):433-43. PubMed ID: 7344171
    [No Abstract]   [Full Text] [Related]  

  • 50. Plasma serotonin concentrations: validation of a sampling technique using long catheters.
    Van Den Berg EK; Schmitz JM; Benedict CR; Prewitt JB; Malloy CR; Willerson JT; Dehmer GJ
    Am J Med Sci; 1987 Nov; 294(5):324-7. PubMed ID: 3425582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stress and platelet activation.
    Andrén L; Wadenvik H; Kutti J; Hansson L
    Acta Haematol; 1983; 70(5):302-6. PubMed ID: 6414223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Determination of platelet factor 4 in blood plasma].
    Blagosklonnyĭ MV; Kuznetsova AD
    Lab Delo; 1987; (5):360-3. PubMed ID: 2441123
    [No Abstract]   [Full Text] [Related]  

  • 53. Platelet factor 4 plasma levels at rest and after exercise in patients with recent myocardial infarction.
    Ek I; Falkenberg C; Bygdeman S; Thunell S
    Acta Med Scand; 1982; 212(1-2):43-6. PubMed ID: 7124459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Platelet factor 4].
    Hoshiyama M; Shibata A
    Nihon Rinsho; 1979 Jun; Suppl():2208-9. PubMed ID: 491112
    [No Abstract]   [Full Text] [Related]  

  • 55. Proceedings: Critical analysis of platelet factor 4 (antiheparin activity) assays.
    Hurlet A; De Beys C; Moriau M; Monsieur A; Schulzen E; Masure R
    Thromb Diath Haemorrh; 1975 Nov; 34(2):573. PubMed ID: 1198465
    [No Abstract]   [Full Text] [Related]  

  • 56. [Platelet factor 4. Properties and clinical significance of its determination (review of the literature)].
    Lavrova LA; Iakunin GA; Smolianitskiĭ AIa
    Lab Delo; 1986; (2):73-6. PubMed ID: 2421065
    [No Abstract]   [Full Text] [Related]  

  • 57. [Platelet factor 4 (PF 4)].
    Kimura A
    Nihon Rinsho; 1995 Mar; 53 Su Pt 2():109-11. PubMed ID: 8753194
    [No Abstract]   [Full Text] [Related]  

  • 58. Coagulation factors and the progress of coronary heart disease.
    Balleisen L; Schulte H; Assmann G; Epping PH; van de Loo J
    Lancet; 1987 Aug; 2(8556):461. PubMed ID: 2887769
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma platelet products and exercise-induced myocardial ischemia.
    Rotmensch HH; Vlasses PH; Carpenter KL; D'Amelio LF; Swanson BN; Ferguson RK
    J Lab Clin Med; 1983 Jul; 102(1):63-9. PubMed ID: 6854135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.